2m 2m 2m 2m 2m 2m 2m
Silexion Therap (SLXN)
NASDAQ
$5.02+$0.16 (+3.27%)
Price as of Jun 03, 2026 7:58 PM EDT- N/AMarket Cap
- -96.50%1-Year Change
- BiotechnologyIndustry
Silexion Therap (SLXN)
$5.02+$0.16 (+3.27%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 155,000 +453.57% | 28,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 155,000 +453.57% | 28,000 N/A | |
Sales and Marketing Expense | 154,000 +1,084.62% | 13,000 N/A | |
Research and Development Expense | -7.1M +22.79% | -5.8M N/A | |
Depreciation and Amortization Expense | 14,000 -44.00% | 25,000 N/A | |
Total Operating Expenses | 11.6M -7.47% | 12.6M N/A | |
Operating Profit | -11.6M -7.47% | -12.6M N/A | |
Interest Income | 155,000 +453.57% | 28,000 N/A | |
Interest Expense | -142,000 +14,100.00% | -1,000 N/A | |
Interest Income and Expense and Net | 13,000 -51.85% | 27,000 N/A | |
Total Nonoperating Income and Expense | 277,000 -92.97% | 3.9M N/A | |
Income before Taxes | -11.9M -27.86% | -16.5M N/A | |
Income Taxes | 3,000 -70.00% | 10,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -11.9M -27.89% | -16.5M N/A | |
Net Income from Continuing Operations Applicable to Common | -11.9M -27.86% | -16.5M N/A | |
Basic EPS and Net Income | 8.96 -66.01% | 26.36 N/A | |
Diluted EPS and Net Income | 8.96 -66.01% | 26.36 N/A | |
Basic Weighted Average Shares | 1.3M +113.12% | 623,846 N/A | |
Diluted Weighted Average Shares | 1.3M +113.12% | 623,846 N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 6.0M +404.72% | 1.2M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6.0M +404.72% | 1.2M N/A | |
Total Current Assets | 6.6M +194.98% | 2.3M N/A | |
Accumulated Depreciation | 80,000 +19.40% | 67,000 N/A | |
Property and Plant and Equipment and Net | 25,000 -16.67% | 30,000 N/A | |
Total Long-Term Assets | 578,000 -5.71% | 613,000 N/A | |
Total Assets | 7.2M +152.01% | 2.9M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 86,000 -9.47% | 95,000 N/A | |
Total Current Liabilities | 2.8M -21.71% | 3.5M N/A | |
Total Long-Term Debt | 1.6M +156,700.00% | 1,000 N/A | |
Total Long-Term Liabilities | 1.9M -44.31% | 3.3M N/A | |
Total Liabilities | 4.6M -32.69% | 6.9M N/A | |
Retained Earnings | -55.2M +27.54% | -43.3M N/A | |
Total Stockholders Equity | 2.6M +165.25% | -4.0M N/A | |
Total Shares Outstanding | 3.1B +69.13% | 1.8B N/A | |
Cash Flow | |||
Cash from Operating Activities | -10.8M +28.86% | -8.4M N/A | |
Capital Expenditures | 9,000 -59.09% | 22,000 N/A | |
Cash from Investing Activities | -14,000 -36.36% | -22,000 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 15.6M +206.43% | 5.1M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -7,504.52% N/A | N/A N/A | |
Return on Assets | -236.40% N/A | N/A N/A | |
Return on Equity | 1,718.90% N/A | N/A N/A | |
Revenue Growth | 453.57% N/A | N/A N/A | |
Current Ratio | 2.41 N/A | N/A N/A | |
Cash Ratio | 2.17 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.64 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.23 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow